Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide profiling of histone modification H3K27ac and CTCF transcription factor binding following VPA treatment in HEK293 cells

ABSTRACT: Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor induces epigenetic changes through histone hyperacetylation which lead to alteration to H3K27ac and CTCF binding in the genome. To determine the effects of VPA on 3D chromatin organization, we performed ChIP-seq on untreated and VPA-treated HEK293T cells. VPA treatment results in elevated H3K27ac marks and slightly reduced CTCF binding, which supports the evidence of active transcription triggered upon histone hyperacetylation induced by VPA.

ORGANISM(S): Homo sapiens

PROVIDER: GSE246314 | GEO | 2026/02/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genome-wide chromatin interaction profiling with Hi-C following VPA treatment in HEK293 cells

Project description:Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor induces epigenetic changes through histone hyperacetylation which lead to chromatin remodeling, including the alteration of compartments, TAD boundaries and chromatin loops. To determine the effects of VPA on 3D chromatin organization, we performed Hi-C sequencing on untreated and VPA-treated HEK293T cells. VPA treatment results in increased A compartments which represents regions associated with active transcription, with more switching from B-to-A compartments. In VPA-treated HEK293T cells, reduced TAD boundaries and increased chromatin loops were also observed, which supports the evidence of active transcription triggered upon histone hyperacetylation induced by VPA.

2026-02-02 | GSE245848 | GEO

Genome-wide gene expression profiling with RNA-seq following VPA treatment in HEK293 cells

Project description:Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor induces epigenetic changes through histone hyperacetylation which could affect gene expression. To determine the effects of VPA on gene expression changes, we performed RNA-seq on untreated and VPA-treated HEK293T cells. Differentially-expressed genes (DEGs) induced by VPA exposure were enriched in signaling processes, regulation of ion transport and extracellular matrix organization, known to be associated with HDAC activities.

2026-02-02 | GSE245856 | GEO

Protein data in PHH after VPA-treatment

Project description:LC-MS/MS protein data of Primary Human Hepatocytes (PHH) exposed to Valproic Acid (VPA) for 3 days daily and 3 days daily exposure followed by 3 days washout.

2018-02-27 | PXD007538 | Pride

Genome-wide H3K9 acetylation state before and after VPA treatment

2011-09-17 | GSE24211 | GEO

Genome-wide H3K9 acetylation state before and after VPA treatment

Project description:Genome-wide maps of the H3K9 acetylation state in embryonic stem cells (ESCs) before and after treatment with low levels of the histone deacetylase (HDAC) inhibitor valproic acid (VPA). ChIP-seq for 3 samples: untreated E14 cells, cells treated with VPA for 4 hrs and cells treated with VPA for 16 hrs. Unprecipitated DNA was used as the input control (Input).

2011-09-17 | E-GEOD-24211 | biostudies-arrayexpress

Gene expression profiles of E14 ESCs treated with low levels of the HDAC inhibitor VPA for 4 hrs

Project description:Gene expression profiles of E14 embryonic stem cells (ESCs) before and after treatment with low levels of the histone deacetylase (HDAC) inhibitor valproic acid (VPA).

2011-09-17 | GSE23957 | GEO

human placenta-derived cell line (JEG-3): Control vs. valproic acid(VPA)-treated

Project description:Transcriptional profiling of human placenta-derived JEG-3 cell line comparing vehicle control with 7.38 mM of valproic acid(VPA)-treated JEG-3 cells for 48 hr. 7.38 mM valproic acid(VPA) induced the 30% inhibiotion of JEG-3 cell proliferation, G1 phase cell cycle arrest and the reduction of cell size. The Goal was to analyze the mechanism of valproic acid-induced adverse effects in placental cells.

2012-10-11 | GSE41441 | GEO

human placenta-derived cell line (JEG-3): Control vs. valproic acid(VPA)-treated

2012-10-11 | E-GEOD-41441 | biostudies-arrayexpress

Epigenetic evidence of an Ac/Dc axis by VPA and SAHA

Project description:Valproic acid (VPA) is one of the most commonly used anti-epileptic drugs with pharmacological actions on GABA and blocking voltage-gated ion channels. VPA also inhibits histone deacetylase (HDAC) activity. Suberoylanilide hydroxamic acid is also a member of a larger class of compounds that inhibit HDACs. At the time of this article, there are 123 active international clinical trials for VPA (also known as valproate, convulex, divalproex, and depakote) and SAHA (vorinostat, zolinza). While it is well known that VPA and SAHA influence the accumulation of acetylated lysine residues on histones, their true epigenetic complexity remains poorly understood. Primary human cells were exposed to VPA and SAHA to understand the extent of histone acetylation (H3K9/14ac) using chromatin immunoprecipitation followed by sequencing (ChIP-seq). Because histone acetylation is often associated with modification of lysine methylation, we also examined H3K4me3 and H3K9me3. To assess the influence of the HDAC inhibitors on gene expression, we used RNA sequencing (RNA-seq).

2024-09-04 | GSE276338 | GEO

Gene expression of VPA and GEM

Project description:Background: Histone deacetylase (HDAC) is strongly associated with epigenetic regulation and carcinogenesis, and its inhibitors induce the differentiation or apoptosis of cancer cells. Valproic acid (VPA) is one of the clinically available HDAC inhibitors. We investigated the anticancer effects of VPA in combination with gemcitabine (GEM) in cholangiocarcinoma cell line, and explored the mechanisms of the anticancer effects using microarray analysis. Methods: A human cholangiocarcinoma cell line (HuCCT1) was used. The anticancer effects of VPA, or gemcitabine (GEM), and the effects of VPA combined with GEM, were studied by cell proliferation assay. The microarray analysis was performed, the genes were picked up using Gene Spring GX11.5, Ingenuity Pathways Analysis (IPA) was performed, and then the gene-expression was determined by RT-PCR. Results: GEM (5nM) and VPA (0.5mM) reduced by 23%, which significantly augmented the anticancer effect of GEM alone or VPA alone (P<0.01). Using the microarray analysis, forty-three genes were identified with the comparison between GEM group and GEM plus VPA combination group. The interactions were shown between genes of the “Cellular Development” relevant to the differentiation of cancer cell using IPA.

2011-02-09 | GSE27036 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data